Novozymes 9M adjusted EBITDA margin rises year-on-year to 37.9%

Bitget2026/11/05 07:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novonesis’ nine-month 2026 adjusted EBITDA margin rose to 37.9% from a year earlier.
Organic sales growth reached 7% for the nine months and 6% in Q3.
The acquisition of MicroBioGen’s remaining 77% stake closed October 1, providing full access to its yeast platform.
The 2026 outlook remains 7-8% organic sales growth, with adjusted EBITDA margin at the higher end of 37-38%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novozymes A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050209OMX_____CNEWS_EN_GNW1001301934_en) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novozymes 9M adjusted EBITDA margin rises year-on-year to 37.9%

You may also like

Crypto prices